Medical Officer Research Coordinator

MUZAMMIL MUSHTAQ, M. D.

***** ********* **, **** *****, IN, 46814

305-***-**** ********.*******@*****.***

QUALIFICATIONS

Dedicated, multilingual Physician with international medical experience and whose culturally diverse background complements a willingness to learn and apply new medical concepts in the study and practice of medicine. Currently seeking interventional Cardiology position to utilize and expand procedural skills for complex coronary interventions and sturtural heart disease. Possesses extensive background working in humanitarian capacity to provide medical care to underserved populations. Compassionate with a tireless work ethic and superior attention to detail. Fluent in Hindi, Urdu, Arabic, and Punjabi. Willing to relocate.

Citizenship:

USA

Examinations:

ECFMG-TOEFL, Passed, Sept. 2003

USMLE, Step 1, Passed, Aug. 2003

USMLE, Step 2 CK (Clinical Knowledge), Passed, Nov. 2004

ECMG-CSA, Passed, Feb. 2004

Step 3 Passed 2009

Certification:

American Board of Internal Medicine 2009

ECFMG, issued Nov. 2004

EDUCATION & HONORS

KING EDWARD MEDICAL COLLEGE, Lahore, Pakistan

M.B.B.S (Doctor of Medicine equivalent), Aug. 2000

Scholarship holder for entire tenure of medical school (sponsored by the Federal Board of Education).

Passed third Professional Examination with honors.

Among top 5 students in third Professional Examination.

Among top 10 in the Final Professional Examination.

2009 Excellence in Clinical Care awarded by Division of Hospital medicine, UMMSM

2010 Excellence in Medical Student teaching awarded by Division of Hospital medicine, UMMSM

Scholarship Grant Stanford Coronary Physiology Course Nov 2016

Scholarship Grant Annual Cardiovascular Research Foundation (CRF) Course Feb 2017 Washington,

DC

Reviewer for the Jourmal of Critical Care Since May 2013

PROFESSIONAL EXPERIENCE

LUTEHRAN HOSPITAL OF INADIANA

INTERVENTIONAL CARDIOLOGIST

FORT WAYNE, IN Aug. 2018 to Present

MUZAMMIL MUSHTAQ, M. D. Page Two

PROFESSIONAL EXPERIENCE

(Continued)

Joined a very busy program as interventional and structural cardiologist involved in high risk coronary and peripheral interventions including VA ECMO, VV ECMO, myocardial biopsies,

CTO interventions, Rotablator, laser atherectomies along with CSI guided peripheral interventions.

Also running the chest pain committee as the cardiologist involved in recredentialing of one of the sister hospital with ACC chest pain accreditation

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

BETH ISRAEL DEACONESS MEDICAL CENTER

CLINICAL AND RESEARCH FELLOW

INTERVENTIONAL CARDIOLOGY FELLOWSHIP PROGRAM BOSTON, MA Jul. 2017-Jun. 2018

Successfully finished interventional cardiology fellowship at BIDMC which is a large teaching hospital affiliated with the Harvard Medical school.

Trained in complex coronary intervention with Rotablator, laser atherectomy, CHIP, CTO, TAVR, Mitral clips, PFO and peripheral interventions’

UNIVERSTY OF MIAMI MILLER SCHOOL OF MEDICINE

CARDIOVASCULAR DISEASES FELLOWSHIP MIAMI, Florida Jul. 2014 –June 2017

Successfully completed fellowship in General Cardiology at University of Miami/Jackson Memorial Hospital which is the 3rd largest hospital in the USA

We rotate at two other hospitals’ including Miami VA and University of Miami Hospital which is the flagship hospital for University of Miami so far have completed more than 6 months of cardiac catheterization training at three different sites.

LONGEVERON LLC, MIAMI, Florida

DEPUTY MEDICAL OFFICER Oct.2015–June 2017

As Deputy Medical Officer for Longeveron LLC, I oversee the safety and compliance of the clinical trials. Longeveron LLC provides significant financial support in excess of $2 million per year for various research projects involving applications of stem cells for treatment of various disease especially focused toward aging frailty. I currently dedicate effort in the amount of 1.8 calendar months per year on such research projects

INTERDISCIPLINARY STEM CELL INSTITUTE UNIVERSTY OF MIAMI MILLER SCHOOL OF MEDICINE, MIAMI, FLORIDA

POSTDOC FELLOW/JUNIOR FACULTY Jul. 2013–Jun. 2014

Actively involved with the Interdisciplinary Stem Cell Institute at the University of Miami, in the role of post-doctoral fellow/junior faculty.

Working as the PI of the preclinical swine models in Dr. Hare's lab which generates data for the clinical studies. Also working in the capacity of Co-PI in multiple phase I/II clinical trials studying the efficacy, safety and optimal delivery methods for transednocardial stem cell injections in post myocardial infarction models and dilated cardiomyopathy models

UNIVERSTY OF MIAMI MILLER SCHOOL OF MEDICINE, MIAMI, FLORIDA

HOSPIATL MEDICINE FACULTY ASST PROF OF CLINICAL MEDICINE Jul. 2009–Jun. 2014

MUZAMMIL MUSHTAQ, M. D. Page Three

PROFESSIONAL EXPERIENCE

(Continued)

Worked as full-time faculty in the Division of Hospital Medicine, responsibilities include clinical duties at the affiliated institutions with University of Miami including Jackson Memorial Hospital and Bascom Palmer Eye institute, staffing the resident-run inpatient teaching services, medicine consult services, procedure service with hand held ultrasound guidance, and non-teaching services.

Actively involved in Graduate Medical Education and medical school teaching including leading small groups for problem and case-based learning, Clinical Competency/OSCE examinations and serving in the role of faculty mentor for second year students. Consistently scored perfect evaluation by students as the small group leader. Started a part time role in July 2013Started working as faculty in hospital medicine and was involved

THE MOUNT SINAI SCHOOL OF MEDICINE

INTERNAL MEDICINE RESIDENCY PROGRAM (VA BRONX), New York Jul. 2006 – Jun. 2009

Successfully completed training in internal medicine at the Mount Sinai (Bronx VA) program

The affiliated hospitals are Veterans Affair Hospital in the Bronx and North Central Bronx Hospital which is a city hospital.

THE METHODIST HOSPITAL RESEARCH INSTITUE,

GENITOURINARY ONCOLOGY DIVISION, Houston, Texas Jul. 2005– Jul. 2006

Clinical Research Coordinator

Observe clinical examinations, involved in the disease assessment of patients on study by measurement of the target and non-target lesions on CT scan, MRI and Bone scans.

Actively participate in CME conferences and weekly patient care meetings that also involve interaction with other physicians.

BAYLOR COLLEGE OF MEDICINE,

MICHAEL E. DEBAKEY DEPARTMENT OF SURGERY, Houston, Texas Nov. 2004 – Jul. 2006

Research Assistant

Assist Dr. David H. Berger with research project to define TGF-B signaling pathways that control proteases expression and intestinal epithelial migration in colon cancer.

Process and culture various cell lines; study cell migration assay by Boyden Chambers.

Trained in basic lab techniques including Western Blotting, PCR, and Cell Culture.

FAISAL CLINIC

PRIVATE PRACTICE, Lahore, Pakistan Aug. 2002 –Jan. 2004

Medical Officer

Managed diverse patient population in both in- and out-patient setting in areas of internal medicine, preventive medicine. This was a busy clinic located in the under served area in the heart of old Lahore City.

MAYO HOSPITAL, Lahore Pakistan

Unit I East Medical Ward

Medical Officer (July 2000 – Dec 2002)

Provided independent patient care in the in-patient, out-patient and causality departments.

Provided routine care and admission from the out-patient and emergency department.

MUZAMMIL MUSHTAQ, M. D. Page Four

PROFESSIONAL EXPERIENCE

(Continued)

Supervised house physicians in various departments including the causality department.

Oversaw the performance of various procedures including paracentesis, central venous catheterization, lumbar punctures, peritoneal dialysis, liver biopsies, thoracentesis, endo-tracheal intubations, and ventilator care.

Attended and actively participated in clinico-pathological conferences, teaching rounds, case discussions, and mortality conferences.

Assisted in routine Ultrasonography, Echocardiography, Gastroscopy, and Colonoscopy.

House Physician (Jan. 2000 – June 2000)

Attended to emergency department, provided treatment to patients on an in- and out-patient basis.

Attended to out-patient and casualty departments, provided routine patient care and case presentation.

Conducted teaching rounds, completed rotation in diabetic, hypertensive and dialysis unit.

Performed lumbar punctures, peritoneal dialysis, liver biopsies, para- and thoracentesis, and central venous catheterization.

Teaching Unit Chest and Thoracic Surgery

House Surgeon (Nov. – Nov. 1999)

Assisted in major and minor operations, bronchoscopies and chest intubations.

Unit I North Surgical Ward

House Surgeon (July – Dec. 1999)

Completed rotations on the surgical floor and in emergency department; treated surgical and trauma patients.

Performed eight appendectomies and two hernia repairs under the guidance of the faculty surgeons, passed one CVP line; preformed one herniotomy and one repair of varicocele.

RESEARCH EXPERIENCE

UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE, Miami, Florida

Post-doctoral fellow/Junior Faculty/Sub-Principal Investigator (Jan. 2010 –Present)

Actively involved with the Interdisciplinary Stem Cell Institute at the University of Miami, in the role of post-doctoral fellow/junior faculty

These are few of the previous project that I was involved as Co-PI.

TAC-HFT-II: A Phase I/II, Randomized, Placebo Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (July 2016–June 2017)

CONCERT-HF: A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and c-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects with Ischemic Heart Failure (Jun. 2016–June 2017)

A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Transendocardial Injection of IxmyelocelT in Subjects with Heart

MUZAMMIL MUSHTAQ, M. D. Page Five

RESEARCH EXPERIENCE

(Continued)

Failure Due to Ischemic Dilated Cardiomyopathy. This study is designed to evaluate the safety and effectiveness of ixmyelocelT, an experimental product that contains your own cells IxmyelocelT contains cells which have been expanded from the subjects own bone marrow cells. (July 2015–June 2017)

Cell004: A Phase 2b, Double Blind, Placebo Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR (AAV1/SERCA2a) in Subjects with Heart Failure. The study primary objective is to determine the efficacy of a single intracoronary infusion of 1 x 1013 DRP MYDICAR added to an optimal HF regimen in patients with ischemic or dilated cardiomyopathy and moderate to advanced symptoms of heart failure (HF) by reducing the frequency and/or delaying HF related hospitalizations compared to placebo treated patients. Secondary objectives will include assessment of the safety of MYDICAR by determining the incidence and severity of AEs and changes in laboratory parameters. In addition, a

third-party vendor will be employed to assess the resource utilization, health related quality of life

and const effectiveness of MYDICAR treatment compared to standard of care alone. (July 2015–

June 2017)

Neurocardiogenic Injury in Subarachnoid Hemorrhage

We designed a prospective observational study evaluating the clinical predictors of cardiac complications and long term outcome in the patients admitted with aneurysmal subarachnoid hemorrhage. The major benefits of this study are defining prevalence and risk/protective

factors, evaluating intermediate to long term neurocardiovascular outcome and expanding our understanding of the cardiac complications related to neurologic injury in patients with SAH. As the nature of the study which is observational and questionnaire design, this study carries a minimal risk including psychological distress and anxiety during follow up interviewing and cognitive testing. We hypothesize that the cardiac complications in this population is related to a good long-term prognosis

and catecholamine related medications may impact to the clinical course of disease. The findings from this study may help to develop an evidence-based treatment. (May 2015– June 2017)

TEVA: A Double-Blind, Randomized, Sham-Procedure-Controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP-41750) in Patients With Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology. This is an event-driven study and the study duration will be determined by the number of HF-MACE events. Patients are expected to participate in this study until the required number of HF-MACE occurs. The last patient enrolled must be followed for a minimum of 6 months.

The primary objectives of this study are to:

determine whether transendocardial delivery of 150 million (M) allogeneic human bone marrow-derived MPCs (cep-41750) administered during a single index cardiac catheterization and intracardiac mapping procedure is more effective than a scripted sham cardiac mapping and cell delivery procedure in patients with chronic HF due to LV systolic dysfunction who have received optimal

medical/revascularization therapy (April 2015– June 2017)

ELPIS: Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients with Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.

This is a drug study involving administration of allogenic hMSCs to pediatric patients. Objectives:

MUZAMMIL MUSHTAQ, M. D. Page Six

RESEARCH EXPERIENCE

(Continued)

Primary: Evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavo pulmonary Anastomosis (BDCPA) or total cavopulmonary connection (TCPC) surgeries for hypoplastic left heart syndrome (HLHS) patients.

Secondary: Observe effects on clinical outcomes including right ventricular myocardial function, severity of tricuspid regurgitation, tricuspid valve annulus, incidence of serious adverse events, re-hospitalizations, changes in health status, the need for transplantation, or mortality. (Sept. 2014– June 2017)

CRATUS: A Phase I/II, Randomized, Blinded and Placebo controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Aging Frailty. AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients with Aging FRAilTy via IntravenoUS Delivery. This is an ongoing clinical trial. There are multiple infusions being given to

the patient every six months so far, we have infused three stem cell infusion to one arm under

CRATUS-i3. (Dec. 2013– June 2017)

The TRIDENT Study: A phase II Randomized, Blinded Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Mesenchymal Stem Cells in Patients with Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.

The TRIDENT protocol proposes the use of a percutaneous injection catheter (Biocardia Helical Infusion Catheter) as a delivery method for human mesenchymal stem cells (hMSCs). The protocol involves use of allogeneic bone marrow derived mesenchymal cells, cultured ex vivo. The Primary Objective of this study is to demonstrate the safety of allogeneic hMSCs administered by transendocardial injection in patients with chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI). The Secondary Objective is to demonstrate the efficacy of allogeneic

hMSCs administered by transendocardial injection in patients with chronic ischemic left ventricular dysfunction secondary to MI. (June 2013– June 2017)

PACE: clinical and MR Imaging Assessments in Patients with Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells. Patients with Intermittent Claudication Injected with ALDH Bright Cells (PACE). (May 2013– June 2017)

A Phase I, Randomized, Blinded and Placebo Controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Idiopathic Pulmonary Fibrosis. Study primary objective is to determine the safety and tolerability of intravenous allo hMSCs in patients with IPF. Idiopathic Pulmonary Fibrosis (IPF) is a progressive and debilitating lung disease characterized by interstitial fibrosis with decreasing lung volumes and

pulmonary insufficiency eventually resulting in death. (Feb. 2013– June 2017)

Studying Endothelial Function and Endothelial Progenitor Stem Cells Colonies before and after Heart Mesenchymal Stem Cell Transplantation.The primary object is to study those pleotropic effects of mesenchymal stem cell transplantation we will conduct a prospective trial where we will measure in vivo endothelial function (the brachial artery method flow mediated dilatation percent change) before and after the cell injection. We will also study the effects of mesenchymal stem cell

MUZAMMIL MUSHTAQ, M. D. Page Seven

RESEARCH EXPERIENCE

(Continued)

transplantation on the endothelial progenitor stem cells function by measuring the ability of patients to produce endothelial progenitor stem cells colonies (the Colony Forming Unit Hill Colony Assay).

(Aug. 2011–Present)

Gene Expression Profiling and Prognosis in Cardiomyopathy.

Primary: To validate a previously discovered molecular signature that accurately predicts the long-term prognosis of patients diagnosed with new onset heart failure and/or cardiomyopathy in an independent sample. To grow cardiac stem cells from a biopsy sample to test the hypothesis that cardiac stem cell growth and quality predict outcome in patients with heart failure.

Secondary: To correlate the gene expression levels of an established cardiac biopsy derived multigene biomarker with corresponding gene expression profiles from peripheral blood mononuclear cells (PBMCs). The risks of this study include: Catheterization with Heart Biopsy (part of the standard of care biopsy) The following is a list of risks and discomforts related to a heart biopsy: Unlikely risks: bleeding, infection, serious and long-lasting heart rhythm problems, injury to the pulmonary artery, blood clots in the lungs, and damage to the walls of the heart. (Jan. 2010– June 2017)

THE BRONX VETERANS HOSPITAL, NEW YORK, NEW YORK

Resident / Lab assistant (July 2007–Jun, 2009)

Worked in the laboratory of Dr. Paul Riska studying the prevalence of epidemic clostridium diffcile strain in the general community. I worked as a lab assistant during residency training

THE METHODIST HOSPITAL RESEARCH INSTITUE,

GENITOURINARY ONCOLOGY DIVISION, Houston, Texas

Senior Clinical Research Coordinator (Jul. 2005– Jul. 2006)

Responsibilities include running Phase I and Phase II Clinical Trials for the treatment of Progressive Renal Cell Carcinoma and Prostate Cancer along with taking histories, informed consents, screening,

and enrolling patients on the studies. Received hands on clinical experience in GU Oncology setting as well as direct communication with the patients and their families about their health issues on daily

basis. Discuss the study protocol, mechanism of action of study drugs and expected side effects of the treatment with the patients and their families. Report the adverse events experienced by the patient to the Principal Investigator, Study sponsors, IRB and FDA. Observed clinical examinations, involved in the disease assessment of patients on study by measurement of the target and non-target lesions on CT scan, MRI and Bone scans. Actively participated in CME conferences and weekly patient care meetings that also involve interaction with other faculty members.

BAYLOR COLLEGE OF MEDICINE,

MICHAEL E. DEBAKEY DEPARTMENT OF SURGERY, Houston, Texas

Post-doctoral fellow (Nov. 2004 – Jul. 2006)

Worked as a volunteer in the lab of Dr. Berger on a research project to define TGF-B signaling pathways that control proteases expression and intestinal epithelial migration in colon cancer. The duties included process and culture various cell lines and study cell migration assay by Boyden Chambers. Trained in basic lab techniques including Western Blotting, PCR, and Cell Culture.

MUZAMMIL MUSHTAQ, M. D. Page Eight

VOLUNTEER EXPERIENCE

UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE, Miami, Florida Volunteer Assist Professor of Medicine (Jun. 2015 –Present)

I hold a volunteer faculty appointment in department of medicine in the division of hospital medicine

UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE, Miami, Florida

Member Admissions Committee (Jul.2011 –Jun.2014)

The Admissions Committee member is charged with the responsibility of selecting, evaluating and admitting to the School of Medicine the most academically, experientially and personally qualified candidates. Each committee member is expected to participate in an Admissions Committee orientation program, conduct 15-25 evaluation interviews, write interview reports for each, review and rank applicants weekly, and attend approximately 20 Committee meetings during the “interview year” which runs from September through March.

EASTERN ATLANTIC STUDENT RESEARCH FORUM (ESRF), Miami, Florida

Faculty Judge

ESRF is a four-day international symposium held at the University of Miami Leonard M. Miller School of Medicine in Miami, Florida. Each year, ESRF selects medical, graduate, DO/PhD, and MD/PhD students to present novel basic science and clinical research in multiple biomedical fields. Abstracts are submitted from over sixty universities. I have been invited to judge the poster session every year since 2011

UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE, Miami, Florida

DIVISION OF HSOPITAL MEDICINE

Member at Large Clinical Operations Committee (Feb.2010–Jul.2013)

As member of this committee, you are responsible for ensuring the smooth clinical practice of the division and deals with challenges which come across on daily basis. All the new changes, policies,

and procedure planned for the division are discussed and critiqued on this platform before presenting to the entire faculty in the faculty meetings.

AMERICAN RED CROSS HOUSTON CHAPTER, Houston, Texas

Katrina Relief Volunteer (Sept.2005- Jun. 2006)

Worked as a Red Cross Volunteer for the Katrina victim evacuees in Houston. Provided the medical help needed for the people affected by the aftermath of the hurricane.

WORLD HEALTH ORGANIZATION - STATE HEALTH DEPARTMENT, Lahore, Pakistan

WHO & State Health Department of Pakistan launched a joint endeavor in 1997 to make Pakistan a polio free Country. Two doses of OPV were given in a door-to-door campaign at an interval of two months.

Annual Polio Day Coordinator (Sept. 1999 – Feb. 2000)

Educated and trained volunteers in the proper storage and usage of OPV vaccine.

Administered and coordinated procedures for the safe handling of the vaccine at regional and local camps

MUZAMMIL MUSHTAQ, M. D. Page Nine

VOLUNTEER EXPERIENCE

(Continued)

WORLD HEALTH ORGANIZATION (Continued)

Volunteer (April 1997 – June 1997)

Educated other volunteers from the community regarding the procedure and safe handling of vaccine.

Assisted volunteers in a door-to-door administration campaign of the OPV vaccine.

YEAR BOOK PUBLICATION, Lahore, Pakistan April – Oct. 1998

Coordinator

Arranged for printing and distribution of yearbook among King Edward Medical College students.

Gathered quotes from students and faculty; submitted to editors.

ANNUAL SPORTS DAY ORGANIZATION COMMITTEE, Lahore, Pakistan Dec. 1997 – Feb. 1998

Member

Oversaw and coordinated organization of sports day event for students and faculty to take part in various recreational activities.

Scheduled races and presented awards to the winners.

KEMCOL, Lahore, Pakistan Nov. 1997 – Feb. 1998

Official annual magazine of King Edward Medical College.

Class Representative

Responsible for motivating students to write for KEMCOL, collected material provided by students, short listed the materials and provided materials to the editors.

DEPARTMENT OF COMMUNITY MEDICINE, Lahore, Pakistan Sept. 1996 – July 1997

The Department of Community Medicine at King Edward Medical College arranged field visits to rural areas in fourth year of medical school under the supervision of the faculty professors. The purpose was to offer free medical check-ups, counseling and provided medicines to poor and deprived people of the community.

Field Associate

Visited different undeserved areas every third week throughout fourth year of medical school.

CLASS FUNCTION ORGANIZATION COMMITTEE, Lahore, Pakistan Sept. 1995 – Aug. 1996

Committee organized annual class function as well as recreation trips and group dinners.

In-Charge

Assisted in the organization of the first two functions.

STUDENT ORGANIZATION FOR BLOOD DONATIONS, Lahore, Pakistan Nov. 1993 – Aug. 1997

A non-profit organization at King Edward Medical College supervised by faculty professor and run by the medical students to arrange for free supply of blood to needy patients.

MUZAMMIL MUSHTAQ, M. D. Page Ten

VOLUNTEER EXPERIENCE

(Continued)

Executive Member

Ensured blood-grouping, cross- matching, screening for hepatitis B & C, and HIV was properly done before each collection.

STUDENT PATIENT WELFARE SOCIETY, Lahore, Pakistan Sept. 1997 – Dec. 1998

A non-profit society supervised by King Edward Medical College faculty whereby members provide medical care and financial counseling.

Member

Provided counseling to the patients and assisted them in managing their financial needs; provided poor patients with free medicines.

PUBLICATIONS & PRESENTATIONS

Peer Reviewed Journal Articles

Florea V, Rieger AC, Difede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Lowery MH et al Dose Comparison Study of Allogenic Mesecnchymal Stem Cells in Patients with Ischemic Cardiomyopathy (The TRIDENT Study) Circ Res. 2017 Sep 18. pii: CIRCRESAHA.117.311827. doi: 10.1161/CIRCRESAHA.117.311827. [Epub ahead of print] PMID:28923793

Hare JM, DiFede DL, Castellanos AM, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M,

Lowery MH et al Randomized Comparison of Allogeneic Vs. Autologous Mesenchymal Stem Cells for

Non-lschemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017 Feb 7;69(5):526-537. doi: 10.1016/j.jacc.2016.11.009. Epub 2016 Nov 14.

Cited in PubMed; PMI : 27856208.

Pub Status: Published.

Golpanian S, DiFede D, Khan A, Schulman I, Pujol MV, Heldman AW, Miki R, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, et. al.Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty

Journal of Gerontology: Medical Sciences. 2016, Nov;

Pub Status: Submitted

Karantalis V, Suncion-Loescher VY, Bagno L, Golpanian S, Wolf A, Sanina C, Premer C, Kanelidis AJ, McCall F,Wang B, Balkan W, Rodriguez J, Rosado M, Morales A, Hatzistergos K, Natsumeda M, Margitich I, Schulman IH,Gomes SA, Mushtaq M, DiFede DL, Fishman et al

Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy.

Journal of American College of Cardiology. 2015, Nov; 66(18): 1990-9.

Cited in PubMed; PMID: 26516002.

Pub Status: Published.

Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM study).

Journal of Cardiovascular Translational Research. 2014, Dec; 7(9): 769-780.

MUZAMMIL MUSHTAQ, M. D. Page Eleven

PUBLICATIONS

(Continued)

Cited in PubMed; PMID: 25354998

Pub Status: Published.

Mushtaq M, Cohn SL Perioperative beta-blockers in noncardiac surgery: the evidence continues to evolve. Cleveland Clinic Journal of Medicine. 2014, Aug; 81(8): 501-512.

Cited in PubMed; PMID: 2508598.

Pub Status: Published.

Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, DiFedeVelazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker J, Altman P, Mushtaq M, et al

Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial

Circulation Research. 2014, Apr; 114(8): 1292-1301.

Cited in PubMed; PMID: 24449819.

Pub Status: Published.

Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, Fishman J, Pattany P,

McNiece I, Conte J, Schulman S, Wu K, Shah A, Breton E, Davis-Sproul J, Schwarz R, Feigenbaum G,

Mushtaq M, Suncion VY, Lardo AC, Borrello I, Mendizabal A, et al

Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue

perfusion, and fibrotic burden when administered to patients undergoing coronary artery

bypass grafting

Circulation Research. 2014, Apr; 114(8): 1302-10.

Cited in PubMed; PMID: 24565698.

Pub Status: Published.

Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY at al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic

cardiomyopathy: the TAC-HFT randomized trial.

JAMA. 2014, Jan; 311(1): 62-73.

Cited in PubMed; PMID: 24247587.

Pub Status: Published.

Contact this candidate